How much funding has Alveus Therapeutics raised?

Alveus Therapeutics has raised $197.0M in total funding, most recently a Series A round.

Who are Alveus Therapeutics's investors?

Alveus Therapeutics's investors include Andera Partners, Omega Funds, New Rhein, Jeito Capital, Novo Holdings A/S, Sanofi Ventures.

When was Alveus Therapeutics founded?

Alveus Therapeutics was founded in 2024.

Where is Alveus Therapeutics headquartered?

Alveus Therapeutics is headquartered in Philadelphia, Pennsylvania, United States.

What industry is Alveus Therapeutics in?

Alveus Therapeutics operates in Biotech.

How many employees does Alveus Therapeutics have?

Alveus Therapeutics has 11-50 employees.

Alveus Therapeutics

Redefining Weight Management

Philadelphia, United States · Founded 2024 · $197.0M raised

Biotech

Headquarters: Philadelphia, Pennsylvania
Employees: 11–50
Founded: 2024
Business Model: B2B

Website: alveustx.com
Total Funding: $197.0M
Last Round: $37.0M Series AMar 2026
Rounds: 2

About

Alveus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation therapies for obesity and metabolic diseases. Its lead asset ALV-100 is currently in Phase 1b clinical trials, targeting sustainable weight loss with superior tolerability and reduced treatment burden. The company was founded in early 2024 and raised a $197 million Series A to advance its differentiated therapeutic pipeline.

Summary

Alveus Therapeutics is a Biotech company based in Philadelphia, United States, founded in 2024. It has raised $197.0M in total across 2 rounds, most recently a $37.0M Series A round in Mar 2026. Investors include Andera Partners, Omega Funds and New Rhein.